Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Operating expenses:    
Research and development $ 913,972 $ 321,439
General and administrative 1,528,778 782,846
Total operating expenses 2,442,750 1,104,285
Other income, net:    
Interest income 317 163
Other income, net 0 10
Change in warrant liability 0 223,172
Interest expense 0 (1,920,146)
Total other income (expense), net 317 (1,696,801)
Net loss (2,442,433) (2,801,086)
Deemed dividend on preferred stock 0 (8,222,008)
Net loss attributable to non-controlling interests 0 (5,177)
Net loss attributable to EyeGate Pharmaceuticals, Inc. common stockholders $ (2,442,433) $ (11,028,271)
Net loss per common share - basic and diluted $ (0.31) $ (3.23)
Weighted average shares outstanding - basic and diluted 7,846,616 3,417,509
Net loss $ (2,442,433) $ (2,801,086)
Other comprehensive income (loss):    
Foreign currency translation adjustments (563) 51,325
Net loss attributable to non-controlling interests 0 (5,177)
Other comprehensive income attributable to non-controlling interests 0 32,967
Comprehensive income (loss) attributable to non-controlling interests 0 27,790
Comprehensive loss attributable to EyeGate Pharmaceuticals, Inc. common stockholders $ (2,442,996) $ (2,721,971)